TY - JOUR
T1 - Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation
T2 - Where Do We Stand?
AU - Potdar, Rashmika
AU - Varadi, Gabor
AU - Fein, Joshua
AU - Labopin, Myriam
AU - Nagler, Arnon
AU - Shouval, Roni
N1 - Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2017/11
Y1 - 2017/11
N2 - Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment for many hematologic disorders. Maximizing the benefit of transplantation for disease control while minimizing the risk for associated complications remains the field's leading challenge. This challenge has prompted the development of multiple prognostic scoring systems over the last 2 decades. Prognostic scores can be used for informed decision making, better patient counseling, design of interventional trials, and analysis of prospective and retrospective data. They are also helpful in treatment allocation and personalization according to predicted risk. A better understanding of the molecular and cytogenetic features of the disease, along with the advent of novel therapies, has increased the need for reliable prognostication of which patients will benefit most from transplantation. Here we review the clinical role of the prognostic systems currently in clinical use, examining both their strengths and their limitations.
AB - Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment for many hematologic disorders. Maximizing the benefit of transplantation for disease control while minimizing the risk for associated complications remains the field's leading challenge. This challenge has prompted the development of multiple prognostic scoring systems over the last 2 decades. Prognostic scores can be used for informed decision making, better patient counseling, design of interventional trials, and analysis of prospective and retrospective data. They are also helpful in treatment allocation and personalization according to predicted risk. A better understanding of the molecular and cytogenetic features of the disease, along with the advent of novel therapies, has increased the need for reliable prognostication of which patients will benefit most from transplantation. Here we review the clinical role of the prognostic systems currently in clinical use, examining both their strengths and their limitations.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Nonrelapse mortality
KW - Prognosis
KW - Risk score
UR - http://www.scopus.com/inward/record.url?scp=85028770084&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.07.028
DO - 10.1016/j.bbmt.2017.07.028
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 28797781
AN - SCOPUS:85028770084
SN - 1083-8791
VL - 23
SP - 1839
EP - 1846
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -